Destiny Pharma is a clinical phase biotechnology company dedicated to infection prevention. The company has two late stage clinical programmes and an earlier preclinical pipeline. The strategy is to build strong clinical data packages and then seek partners for the final clinical studies and commercialisation.
XF-73 Nasal is being developed from our proprietary XF platform and is being prepared for Phase 3 studies to prevent post-surgical staphylococcal infections. The unique attributes of this product means it could become the market leader for pre-surgery decolonisation to prevent post-surgical infections where peak sales could reach $1 billion.
Destiny Pharma is also developing the world’s most advanced single strain, live bio-therapeutic product which is the non-toxigenic Clostridioides difficile strain M3 – for the prevention of recurring C. difficile gut infections (CDI). This product is preparing for Phase 3 clinical trials and could deliver peak sales of over $0.5 billion.
The company’s earlier stage pipeline is focused on other indications including two, separate dermal programmes incorporating its XF platform. Destiny Pharma is also collaborating with SporeGen on a novel SPOR-COV® innate immune system boosting nasal spray for the prevention of COVID-19 and influenza.